Healthcare
Exclusive insider sentiment analysis for the Healthcare sector. Track real-time Director purchases and institutional money flow to identify high-conviction opportunities before the market reacts.
| Filing Date | Trade Date | Ticker | Company Name | Reporting Person | Relationship | Industry | Type | Price | Qty | Total, $ | Owned After | Change, % |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-07-28 01:36 | 2026-07-27 | UTHR | UNITED THERAPEUTICS Corp | ROTHBLATT MARTINE A | Director, Officer; Chairperson & CEO | Drug Manufacturers - Specialty & Generic | OPT+S | $530.42 | 9,500 | $5,038,971 | 324,443 | -2.8% |
| 2026-07-27 23:30 | 2026-07-23 | OLMA | Olema Pharmaceuticals, Inc. | Harmon Cyrus | Director | Biotechnology | SALE | $11.65 | 25,000 | $291,163 | 702,770 | -3.4% |
| 2026-07-27 22:59 | 2026-07-27 | EW | Edwards Lifesciences Corp | Zovighian Bernard J | Director, Officer; CEO | Medical Devices | SALE | $83.93 | 2,921 | $245,134 | 8,916 | -24.7% |
| 2026-07-27 20:33 | 2026-07-27 | CYTK | CYTOKINETICS INC | Blum Robert I | Director, Officer; President & CEO | Biotechnology | OPT+S | $80.87 | 7,500 | $606,525 | 377,820 | -1.9% |
| 2026-07-27 20:05 | 2026-07-23 | TWST | Twist Bioscience Corp | Finn Patrick John | Officer; President and COO | Diagnostics & Research | SALE | $93.89 | 2,238 | $210,133 | 272,566 | -0.8% |
| 2026-07-27 20:06 | 2026-07-23 | IRD | Opus Genetics, Inc. | Gagnon Robert E. | Officer; Chief Financial Officer | Biotechnology | SALE | $2.95 | 7,783 | $22,942 | 584,375 | -1.3% |
| 2026-07-27 20:07 | 2026-07-23 | IRD | Opus Genetics, Inc. | Magrath George | Director, Officer; Chief Executive Officer | Biotechnology | SALE | $2.95 | 9,475 | $27,926 | 1,731,869 | -0.5% |
| 2026-07-27 20:07 | 2026-07-23 | IRD | Opus Genetics, Inc. | SCHACHLE JOSEPH K | Officer; Chief Operating Officer | Biotechnology | SALE | $2.94 | 4,644 | $13,653 | 291,440 | -1.6% |
| 2026-07-27 20:08 | 2026-07-23 | IRD | Opus Genetics, Inc. | YERXA BENJAMIN R | Director, Officer; President | Biotechnology | SALE | $2.97 | 7,429 | $22,064 | 704,106 | -1.0% |
| 2026-07-27 19:25 | 2026-07-27 | ANIX | Anixa Biosciences Inc | KUMAR AMIT | Director, Officer; Chief Executive Officer | Biotechnology | BUY | $3.37 | 3,188 | $10,744 | 647,000 | +0.5% |
| 2026-07-27 13:00 | 2026-07-24 | ANIX | Anixa Biosciences Inc | KUMAR AMIT | Director, Officer; Chief Executive Officer | Biotechnology | BUY | $3.73 | 3,000 | $11,190 | 643,812 | +0.5% |
| 2026-07-27 10:55 | 2026-07-24 | UTHR | UNITED THERAPEUTICS Corp | ROTHBLATT MARTINE A | Director, Officer; Chairperson & CEO | Drug Manufacturers - Specialty & Generic | OPT+S | $531.74 | 9,500 | $5,051,519 | 324,443 | -2.8% |
| 2026-07-27 10:15 | 2026-07-23 | GLSI | Greenwich LifeSciences, Inc. | Patel Snehal | Director, Officer, 10% owner; CEO and CFO | Biotechnology | BUY | $13.06 | 3,600 | $47,018 | 5,607,702 | +0.1% |
| 2026-07-25 01:00 | 2026-07-22 | SRZN | Surrozen, Inc./DE | TCG Crossover GP II, LLC | 10% owner | Biotechnology | SALE | $21.25 | 325,000 | $6,906,250 | 574,047 | -36.1% |
| 2026-07-24 21:59 | 2026-07-24 | IMVT | Immunovant, Inc. | Pande Atul | Director | Biotechnology | OPT+S | $39.80 | 1,500 | $59,700 | 116,731 | -1.3% |
| 2026-07-24 21:57 | 2026-07-23 | IMVT | Immunovant, Inc. | Stout Jay S | Officer; Chief Technology Officer | Biotechnology | SALE | $38.69 | 2,857 | $110,537 | 205,341 | -1.4% |
| 2026-07-24 21:57 | 2026-07-23 | IMVT | Immunovant, Inc. | Girao Tiago | Officer; Chief Financial Officer | Biotechnology | SALE | $38.69 | 6,798 | $263,015 | 240,798 | -2.7% |
| 2026-07-24 21:26 | 2026-07-22 | NTLA | Intellia Therapeutics, Inc. | Dulac Edward J III | Officer; EVP, Chief Financial Officer | Biotechnology | SALE | $11.25 | 8,111 | $91,249 | 148,175 | -5.2% |
| 2026-07-24 21:02 | 2026-07-23 | INSM | INSMED Inc | Lewis William | Director, Officer; Chair and CEO | Biotechnology | OPT+S | $106.06 | 10,700 | $1,134,890 | 259,058 | -4.0% |
| 2026-07-24 21:11 | 2026-07-22 | DYAI | DYADIC INTERNATIONAL INC | Francisco Trust under agreement dated February 28, 1996 | 10% owner | Biotechnology | SALE | $1.31 | 95,392 | $124,954 | 3,280,272 | -2.8% |
| 2026-07-24 20:51 | 2026-07-22 | ONC | BeOne Medicines Ltd. | Lee Chan Henry | Officer; SVP, General Counsel | Biotechnology | OPT+S | $325.00 | 1,669 | $542,425 | 0 | -100.0% |
| 2026-07-24 20:57 | 2026-07-22 | BFLY | Butterfly Network, Inc. | ROTHBERG JONATHAN M | Director | Medical Devices | SALE | $6.47 | 659,913 | $4,269,505 | 0 | -100.0% |
| 2026-07-24 20:30 | 2026-07-22 | LQDA | Liquidia Corp | Bloch Stephen M | Director | Biotechnology | SALE | $88.93 | 200,000 | $17,786,400 | 501,477 | -28.5% |
| 2026-07-24 20:30 | 2026-07-23 | UTHR | UNITED THERAPEUTICS Corp | ROTHBLATT MARTINE A | Director, Officer; Chairperson & CEO | Drug Manufacturers - Specialty & Generic | OPT+S | $528.58 | 9,500 | $5,021,520 | 324,443 | -2.8% |
| 2026-07-24 20:05 | 2026-07-22 | ACOG | Alpha Cognition Inc. | Opaleye Management Inc. | 10% owner | Biotechnology | BUY | $7.82 | 200,086 | $1,565,493 | 2,995,193 | +7.2% |
| 2026-07-24 16:33 | 2026-07-14 | GDTC | CytoMed Therapeutics Ltd | Choo Chee Kong | Director, 10% owner | Biotechnology | BUY | $1.50 | 200,000 | $300,000 | 630,324 | +46.5% |
| 2026-07-24 01:21 | 2026-07-13 | ARTV | Artiva Biotherapeutics, Inc. | RA CAPITAL MANAGEMENT, L.P. | Director, 10% owner | Biotechnology | BUY | $8.94 | 6,522 | $58,307 | 16,817,543 | +0.0% |
| 2026-07-24 01:22 | 2026-07-21 | ARTV | Artiva Biotherapeutics, Inc. | RA CAPITAL MANAGEMENT, L.P. | Director, 10% owner | Biotechnology | BUY | $9.76 | 264,586 | $2,583,312 | 17,242,483 | +1.6% |
| 2026-07-23 23:34 | 2026-07-21 | ADPT | Adaptive Biotechnologies Corp | ROBINS HARLAN S | Officer; Chief Scientific Officer | Biotechnology | OPT+S | $21.89 | 492,400 | $10,780,409 | 812,058 | -37.7% |
| 2026-07-23 22:39 | 2026-07-21 | MLYS | Mineralys Therapeutics, Inc. | Warren Eric | Officer; Chief Commercial Officer | Biotechnology | OPT+S | $26.87 | 7,438 | $199,885 | 38,400 | -16.2% |
| 2026-07-23 20:36 | 2026-07-22 | UTHR | UNITED THERAPEUTICS Corp | ROTHBLATT MARTINE A | Director, Officer; Chairperson & CEO | Drug Manufacturers - Specialty & Generic | OPT+S | $530.57 | 9,500 | $5,040,380 | 324,443 | -2.8% |
| 2026-07-23 20:28 | 2026-07-21 | ACRV | Acrivon Therapeutics, Inc. | Miller Mary | Officer; Chief Legal Officer | Biotechnology | SALE | $1.76 | 573 | $1,008 | 82,194 | -0.7% |
| 2026-07-23 20:05 | 2026-07-21 | MLTX | MoonLake Immunotherapeutics | Reich Kristian | Officer; Chief Scientific Officer | Biotechnology | SALE | $20.02 | 52,448 | $1,049,962 | 2,712,298 | -1.9% |
| 2026-07-23 20:09 | 2026-07-21 | CYTK | CYTOKINETICS INC | Malik Fady Ibraham | Officer; EVP Research & Development | Biotechnology | OPT+S | $80.59 | 3,500 | $282,065 | 153,902 | -2.2% |
| 2026-07-23 20:10 | 2026-07-21 | RANI | Rani Therapeutics Holdings, Inc. | IMRAN MIR A | Director, 10% owner | Biotechnology | BUY | $0.69 | 36,000 | $24,840 | 2,119,334 | +1.7% |
| 2026-07-22 23:31 | 2026-07-20 | LQDA | Liquidia Corp | Bloch Stephen M | Director | Biotechnology | SALE | $79.97 | 78,596 | $6,285,251 | 701,477 | -10.1% |
| 2026-07-22 21:50 | 2026-07-20 | ENSG | ENSIGN GROUP, INC | Agwunobi John O | Director | Medical Care Facilities | SALE | $171.06 | 392 | $67,056 | 9,503 | -4.0% |
| 2026-07-22 21:03 | 2026-07-20 | ONC | BeOne Medicines Ltd. | OYLER JOHN | Director, Officer; Chief Executive Officer | Biotechnology | OPT+S | $315.28 | 109,713 | $34,590,852 | 0 | -100.0% |
| 2026-07-22 20:30 | 2026-07-21 | ABEO | ABEONA THERAPEUTICS INC. | Vazzano Joseph Walter | Officer; Chief Financial Officer | Biotechnology | SALE | $6.53 | 1,478 | $9,651 | 492,079 | -0.3% |
| 2026-07-22 20:30 | 2026-07-21 | UTHR | UNITED THERAPEUTICS Corp | ROTHBLATT MARTINE A | Director, Officer; Chairperson & CEO | Drug Manufacturers - Specialty & Generic | OPT+S | $532.24 | 9,500 | $5,056,298 | 324,443 | -2.8% |
| 2026-07-22 20:01 | 2026-07-20 | SOPH | SOPHiA GENETICS SA | Camblong Jurgi | Director, Officer; Executive Chairman | Health Information Services | OPT+S | $6.45 | 44,381 | $286,098 | 3,492,822 | -1.3% |
| 2026-07-22 20:05 | 2026-07-20 | SGMT | Sagimet Biosciences Inc. | Kemble George | Director | Biotechnology | SALE | $7.46 | 18,844 | $140,529 | 62,161 | -23.3% |
| 2026-07-22 20:05 | 2026-07-20 | NAMS | NewAmsterdam Pharma Co N.V. | Kooij Louise Frederika | Officer; Chief Accounting Officer | Biotechnology | OPT+S | $30.34 | 105,000 | $3,185,658 | 24,353 | -81.2% |
| 2026-07-22 20:05 | 2026-07-20 | RVTY | REVVITY, INC. | Gonzales Anita | Officer; Vice President and CAO | Diagnostics & Research | SALE | $109.48 | 85 | $9,306 | 7,201 | -1.2% |
| 2026-07-22 20:05 | 2026-07-20 | SGMT | Sagimet Biosciences Inc. | Rozek Elizabeth | Officer; Chief Legal & Admin. Officer | Biotechnology | SALE | $7.76 | 10,545 | $81,832 | 224,414 | -4.5% |
| 2026-07-22 20:05 | 2026-07-20 | SGMT | Sagimet Biosciences Inc. | Happel David | Director, Officer; President & CEO | Biotechnology | SALE | $7.76 | 64,051 | $497,068 | 741,570 | -8.0% |
| 2026-07-22 19:45 | 2026-07-21 | RDGL | VIVOS INC | Weeks Brad Allan | Officer; President | Medical Devices | BUY | $0.05 | 92,000 | $4,600 | 1,471,654 | +6.7% |
| 2026-07-22 13:55 | 2026-07-21 | TOI | Oncology Institute, Inc. | Chernett Jorey | 10% owner | Medical Care Facilities | BUY | $5.27 | 18,000 | $94,860 | 10,648,858 | +0.2% |
| 2026-07-22 01:12 | 2026-07-21 | MGTX | MeiraGTx Holdings plc | Giroux Richard | Officer; CFO & COO | Biotechnology | SALE | $12.51 | 56,000 | $700,560 | 908,530 | -5.8% |
| 2026-07-22 00:50 | 2026-07-20 | AKTS | Aktis Oncology, Inc. | Herrmann Ken | Director | Biotechnology | OPT+S | $24.56 | 4,856 | $119,274 | 0 | -100.0% |
Strategic Analysis
Analyzing insider transactions within the Healthcare sector provides critical insights into institutional sentiment. When multiple executives across different companies in the same industry exhibit similar buying patterns (cluster buying), it often signals an upcoming sector-wide recovery or undervalued market conditions.
Regulatory Transparency
Our platform tracks SEC Form 4 filings in real-time. We differentiate between routine option exercises and open-market purchases to give you a clear view of "Skin in the Game". Understanding the roles of Directors vs. 10% Owners helps prioritize signals that carry the most predictive weight.
UNDERSTANDING THE DATA
FILING DATE: The date and time when the transaction was reported to the SEC. This is when the public first receives the information.
TRADE DATE: The actual day the insider executed the purchase or sale in the market.
INDUSTRY: The specific market sector the company operates in. Useful for identifying broader institutional capital flows across sectors.
OWNED AFTER: The total number of shares held by the insider following the transaction. This highlights the insider's remaining conviction in the company.
CHANGE %: The percentage increase or decrease of the insider's total position. Large percentage changes often carry more weight than the dollar amount alone.
TRADE TYPES DEFINITIONS
BUY: An open market purchase. Typically indicates an insider's belief that the stock is undervalued or poised for growth.
SELL: An open market sale. While often used for diversification or liquidity, large or unexpected sales can be a warning signal.
OPT+S (OPTION EXERCISE & SALE): This occurs when an insider exercises their stock options and sells them immediately. Often part of a structured compensation plan.